Opexa Therapeutics

Opexa Therapeutics
Opexa Therapeutics corporate logo

Opexa Therapeutics NASDAQ: OPXA, formerly known as PharmaFrontiers, is a biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies.

Key products and research include:

Location

Opexa Therapeutics is located in The Woodlands, Texas 30 miles (48 km) north of Houston, Texas. The company has a 10,200 sq ft (950 m2) facility on 3 acres (12,000 m2) in The Woodlands. This location provides space for pipeline development through R & D; a specialized Flow cytometry and Microscopy lab; support of clinical trials with GMP manufacturing Suites; Quality Systems management with Quality Control Laboratory, Regulatory Affairs, Quality Assurance; as well as administrative support space.

External links


Wikimedia Foundation. 2010.

Игры ⚽ Поможем написать курсовую

Look at other dictionaries:

  • Tovaxin — is a novel anti T cell therapeutic vaccine that parallels the concept of autologous cancer vaccines. Instead of modifying cancerous cells, TovaxinTM consists of attenuated autoreactive T cells. Tovaxin is being developed by Opexa Therapeutics in… …   Wikipedia

  • Therapies under investigation for multiple sclerosis — Scientists continue their efforts to create new and better therapies for multiple sclerosis. There are a number of treatments under investigation that may improve function, curtail attacks, or limit the progression of the underlying disease. Many …   Wikipedia

  • Myelin Repair Foundation — The Myelin Repair Foundation (MRF) is a 501(c)3 not for profit organization based in Saratoga, California. The organization applies a collaborative business model to the process of medical research with the aim of accelerating the identification… …   Wikipedia

  • Liste von Multiple-Sklerose-Wirkstoffen in der Erprobung — Für die immunmodulierende Langzeittherapie der Multiplen Sklerose sind derzeit acht Medikamente im deutschen Sprachraum zugelassen: drei Beta Interferone, Glatirameracetat, Mitoxantron, Azathioprin, Natalizumab und Fingolimod. Darüber hinaus gibt …   Deutsch Wikipedia

Share the article and excerpts

Direct link
… Do a right-click on the link above
and select “Copy Link”